Obagi Medical Products, Inc. (Nasdaq:OMPI), a leader in topical aesthetic and therapeutic skin health systems, today announced positive study results at the Fall Clinical Dermatology Conference Meeting showing that use of its ELASTIderm(TM) Decolletage System is highly effective in improving photodamaged skin of the chest and neck, also known as decolletage. The skin care system showed significant improvements in as early as 2 weeks. The treatment was also well tolerated and provided patients with high levels of satisfaction.
“In recent years, it has become clear to me that many women are doing a much better job of protecting their faces from sun damage; however, they continue to neglect their neck and chest area. It is common to see a woman with mild photodamage of their face and a heavily pigmented, rough and wrinkled chest. The results of this study speak for themselves. The system is highly effective, with the most obvious improvements in mottled hyperpigmentation occurring early in treatment, which continued to improve over time, as did wrinkling,” said James Leyden, MD, Emeritus Professor, University of Pennsylvania Health Systems and KGL, Inc., and lead investigator.
ELASTIderm(TM) Decolletage System is the only topical system backed by data from a 24-week clinical study that is designed to treat hyperpigmentation, including age spots and freckles, while reducing the appearance of fine lines and wrinkles. The System works by helping to replenish elasticity and build collagen in the chest and neck area. It is based on the Company’s patented Penetrating Therapeutics(TM) technology that allows for greater penetration across the skin barrier to help stimulate elasticity and increase the overall resiliency of the skin.
“Skin around the neck and chest is often overlooked in the anti-aging treatment process and our system can assist skin care professionals in providing the total rejuvenating results their patients want,” said Steve Carlson, President and Chief Executive Officer of Obagi Medical Products. “We are proud that the ELASTIderm Decolletage System technology can provide patients such significant improvement in the reduction of fine lines and wrinkles, as well as effectively treating hyperpigmentation.”
Study Methodology
Study subjects had a decolletage area with at least moderate levels of photodamage and at least moderate levels of mottled hyperpigmentation, fine wrinkling, or coarse wrinkling. All subjects applied the ELASTIderm(TM) Decolletage System to their entire decolletage twice daily for 24 weeks.
Baseline assessments of the Investigator’s Overall Integrated Assessment of Photodamage, the primary endpoint of the study, showed that all patients had very severe to moderate photodamage at the start of the study. By week 12, 53% of patients had only minimal to mild photodamage, increasing to 69% at week 24.
At the start of the study, all patients had moderate to severe levels of hyperpigmentation associated with sun damage. By week 24, 79% of patients had minimal to no signs of hyperpigmentation.
In addition, prior to treatment, all patients had moderate to severe levels of fine wrinkling. By week 24, 100% of patients had only mild to minimal levels of fine wrinkling.
Overall, 95% of patients were “satisfied” or “very satisfied” with the overall improvement of their decolletage at week 24.
About the ELASTIderm(TM) Decolletage System
The ELASTIderm(TM) Decolletage System is a physician-dispensed skincare system that consists of two clinically proven topical skin treatments — ELASTIderm Skin Lightening Complex and ELASTIderm Wrinkle Reducing Lotion. The ELASTIderm Skin Lightening Complex is formulated with 4% hydroquinone to aid in the gradual lightening of hyperpigmented skin conditions. The ELASTIderm Wrinkle Reducing Lotion is formulated with a proprietary bi-mineral complex with malonic acid that helps replenish elasticity and build collagen.
About Obagi Medical Products, Inc.
Obagi Medical Products develops and commercializes skin health products for the dermatology, plastic surgery, and related aesthetic markets. Using its Penetrating Therapeutics(TM) technologies, Obagi Medical’s products are designed to improve penetration of agents across the skin barrier for common and visible skin conditions in adult skin including chloasma, melasma, senile lentigines, acne vulgaris and sun damage. The history of Obagi’s skin care product introductions is as follows: Obagi Nu-Derm(R), 1988; Obagi-C(R) Rx (the first and only prescription-strength vitamin C and hydroquinone system), 2004; Obagi(R) Professional-C (a line of highly stable vitamin C serums), 2005; Obagi(R) Condition and Enhance for use with cosmetic procedures to enhance patient outcomes and satisfaction, 2006; Obagi ELASTIderm(TM) eye treatment and Obagi CLENZIderm(R) M.D. acne therapeutic systems, 2007; a formulation of Obagi CLENZIderm(R) M.D. Systems for normal to dry skin, June 2007; and Obagi ELASTIderm(TM) Decolletage System, January 2008 and SoluCLENZ Rx Gel for the pharmacy channel in August 2008. Visit www.obagi.com for information.
Forward Looking Statements
There are forward-looking statements contained herein, which can be identified by the use of forward-looking terminology such as the words “believes,””expects,””may,””will,””should,””potential,””anticipates,””plans,” or “intends” and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from the future results, events or developments indicated in such forward-looking statements. Such factors include, but are not limited to the intense competition our products face and will face in the future, the level of market acceptance of our products, the possibility that our products could be rendered obsolete by technological or medical advances, the possibility that we may become involved in intellectual property claims and litigation that could adversely affect the profitability of or our ability to sell our products, the possibility that our products may cause undesirable side effects and the fact that our ability to commercially distribute our products may be significantly harmed if the regulatory environment governing our products changes. A more detailed discussion of these and other factors that could affect results is contained in our filings with the U.S. Securities and Exchange Commission, including our Form 10-K for the year ended December 31, 2007. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. No assurance can be given that the future results covered by the forward-looking statements will be achieved. All information in this press release is as of the date of this press release and Obagi Medical Products does not intend to update this information.
Comments